SLC5A2 and neoplasm: Inhibition of normal glycolysis in tumor cells through targeting SGLT2 may provide a starting point for exploring the potential of empagliflozin as a dual-use drug for the treatment of patients with diabetes and cancer, but further research is needed to provide more detailed data to support this potential use of empagliflozin.